[Nifedine (Adalat): a calcium-inhibitor with effects in angina pectoris]. 1979

S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
August 1978, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
August 1975, Fortschritte der Medizin,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
January 1980, British journal of clinical practice. Supplement,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
January 1976, Catheterization and cardiovascular diagnosis,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
April 1978, Die Medizinische Welt,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
November 1988, Giornale italiano di cardiologia,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
October 1991, Cardiologia (Rome, Italy),
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
March 1979, Drug and therapeutics bulletin,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
August 1982, Herz,
S Hvidt, and L P Gudbjerg, and K H Kristensen, and I Nielsen, and L P Larsen
January 1988, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!